TNF and inflammatory bowel disease: Although a wide range of studies have demonstrated that TNF-α inhibitors are effective therapies for IBD, there are still approximately 40% of patients will experience primary nonresponse (PNR) or secondary loss of response (SLR) (Argollo et al., 2020).